| 2006-07-28: |
Pfizer's Champix( R ) Receives Positive Opinion From CHMP for the Treatment of Smoking Cessation
New York ( PRN/ots ) - - More Than 1.2 Million Europeans Die of Smoking - Related Diseases Each Year; An Estimated US$500 Billion in Global Health - Related Costs by 2010 - Medical Expert: 'Helping smokers quit is one of the most important things a physician can (...) |
| 2004-11-25: |
Aplidin( R ) Enters Phase II Trials in Haematological Cancers
Madrid, Spain, November 25 ( PRN/ots ) - - Aplidin( R ) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti - tumour agent, Aplidin( R ), has commenced Phase II clinical trials (...) |
| 2008-09-16: |
SemBioSys Eligible to Proceed With Phase I/II Plant - Produced Insulin Trial After Submission of IND
Calgary, Canada ( PRN/ots ) - - TSX symbol: SBS SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it is eligible to proceed with its planned Phase I/II human clinical (...) |
| 2007-09-06: |
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992( i )
Ingelheim, Germany ( PRN/ots ) - - New Data on BIBW 2992( i ), a Potent, Irreversible, Second - Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non - US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung (...) |
| 2010-05-12: |
Sanofi - aventis Initiates 10,000 Patient Study With Multaq( R ) in Permanent Atrial Fibrillation
Paris, May 12, 2010 ( PRN/ots ) - Sanofi - aventis announced today the initiation of a multinational, randomized, double - blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq( R ) ( dronedarone ) in over 10,000 patients with permanent atrial fibrillation ( AF ) to reduce major adverse (...) |
| 2010-04-28: |
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL - C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 ( PRN/ots ) - New long - term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74 Prozent and 73.5 Prozent achieved NCEP* and EAS* low - density lipoprotein cholesterol ( LDL - (...) |
| 2007-07-17: |
Grunenthal signs trimegestone licensing agreement for oral contraception
Aachen ( na Originaltextservice ) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi - aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed (...) |
| 2005-08-03: |
Isotechnika Announces Interim Blinded Phase III Psoriasis Results
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis ( SPIRIT ) trial commenced on December 2, 2004 (...) |
| 2005-04-25: |
Isotechnika Announces Preliminary Phase III Psoriasis Results
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to show promising results. The Canadian Phase III Psoriasis trial ( SPIRIT ) which commenced on December 2, 2004, includes a total of (...) |
| 2008-11-11: |
DAIICHI SANKYO and Arqule enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
Munich ( na Originaltextservice ) - Product development agreement focused on ARQ 197, c - Met inhibitor, with discovery collaboration directed toward novel kinase inhibitors ArQule, Inc. ( NASDAQ: ARQL ) and DAIICHI SANKYO Co., Ltd. ( TSE: 4568 ) today announced that they have entered into (...) |
| 2009-05-29: |
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER - 2 Positive Breast Cancer
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib ( HKI - 272 ) in combination with trastuzumab ( Herceptin( R ), Roche ) in HER - 2 positive ( ErbB - 2 positive ) breast cancer, and a separate (...) |
| 2008-12-18: |
Committee for Medicinal Products for Human Use ( CHMP ) Recommends Granting Marketing Authorisation for FIRMAGON( R ) ( degarelix ) for Treatment of Prostate Cancer
Saint Prex, Switzerland ( PRN/ots ) - - New Gonadotropin - Releasing Hormone ( GnRH ) Receptor Antagonist Demonstrates Rapid, Long - Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use ( CHMP ), part of the European Medicines Agency ( EMEA ), has (...) |
| 2005-06-09: |
Cordis Corporation to Appeal Court Ruling
Miami ( PRN/ots ) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the (...) |
| 2007-07-19: |
European Medicines Agency Accepts Review of Marketing Authorization Application for New Antibiotic Doripenem
Beerse, Belgium ( PRN/ots ) - Janssen - Cilag International NV announced today that the European Medicines Agency ( EMEA ) has accepted for review a Marketing Authorization Application ( MAA ) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia ( NP ), including ventilator - associated pneumonia ( VAP ), complicated intra - (...) |
| 2007-06-24: |
Once - Monthly C.E.R.A. Keeps Haemoglobin Stable in High - Risk Kidney Disease Patients With Diabetes or Heart Disease
Basel, Switzerland ( PRN/ots ) - An analysis of two large - scale Phase III maintenance studies on C.E.R.A. has highlighted that two high - risk patient populations - dialysis patients with diabetes and/or coronary artery disease - consistently and safely maintained their haemoglobin ( Hb ) levels at target levels (...) |
| 2005-12-15: |
Sanofi Pasteur Announces Preliminary Trial Results for a First H5N1 Pre - Pandemic Influenza Vaccine Candidate With an Adjuvant
Lyon, France ( PRN/ots ) - - Data Show That the Vaccine is Safe, Demonstrates Immunogenicity and Provides Future Direction for Development Sanofi pasteur, the vaccines business of the sanofi - aventis Group, announced today that preliminary results of clinical trials fielded in France of an (...) |
| 2008-07-21: |
Independent Analyses of the SEAS, SHARP and IMPROVE - IT Studies of Ezetimibe
London ( PRN/ots ) - The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit ( CTSU ) proposed that the hypothesis - generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE - IT trials (...) |
| 2010-06-28: |
New High - Resolution Computer Tomography Data Demonstrates EVISTA( R )'s Effect on Bone Quality in Osteoporotic Patients
Munich, June 28, 2010 ( PRN/ots ) - Interim data from a prospective Investigator Initiated Trial ( IIT ) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA( R ) ( raloxifene 60mg; once - daily, distributed in 34 countries by DAIICHI SANKYO ), indicated (...) |
| 2007-03-12: |
3M Health Care Launches Medical Diagnostics Business Products to Focus on Early Detection of Key Microbes to Help Prevent Spread of Infection
St. Paul, Minnesota ( PRN/ots ) - - For the attention of News and Business Editors 3M Health Care announced today the launch of a new Medical Diagnostics business unit that will focus on developing and commercializing rapid diagnostic product solutions for the detection of (...) |
| 2008-05-30: |
New Report Shows That Despite Poor Survival Rates Lung Cancer is not Prioritized in Europe
Stockholm ( PRN/ots ) - - Report Benchmarks the Current State of Lung Cancer Care Across Europe The fragmented organization and management of lung cancer diagnosis and care in many European countries are exacerbating already poor survival rates amongst patients with the disease. That is the (...) |
| 2009-06-22: |
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza( TM )
San Mateo, California and Staines, England ( PRN/ots ) - - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa - Includes Licensing Option and Development Funding for NGX - 1998 NeurogesX, Inc. ( NASDAQ: NGSX ) and Astellas Pharma Europe Ltd., ( Astellas ), (...) |
| 2006-08-04: |
Medify Solutions Limited - CEO Initial Assessment Statement
Gateshead, England ( PRN/ots ) - From the 1st July 2006 Ian O'Reilly was appointed the Group CEO of the Medify Solutions ( OTC: MFYS ) group of companies. One month into the role, O'Reilly provides the following assessment as to the state of the business. (...) |
| 2008-08-25: |
Phase 1b/2a Program Commences for RVX - 208
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX: RVX ) is pleased to announce that the Phase 1b/2a program for the study of RVX - 208 in subjects with normal lipids and those with low high - density lipoprotein ( HDL ) cholesterol has proceeded (...) |
| 2007-05-11: |
Intervet's Bird Flu Vaccine Receives EU License
Boxmeer, The Netherlands ( PRN/ots ) - Intervet, a leading animal health company, received approval for its bird flu ( avian influenza ) vaccine Nobilis( R ) Influenza H7N1. As a result, Europe now has a licensed vaccine to protect birds against the H7 field strain. Last year the European (...) |
| 2005-03-01: |
Avastin Proven Effective Even in Advanced Colorectal Cancer Patients Who Are Unable to Tolerate Aggressive Chemotherapy
Basel, Switzerland ( PRN/ots ) - - New Study Published Today Provides Further Evidence of the Benefit of Avastin( R ) for Patients With Advanced Colorectal Cancer Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new (...) |
| 2009-05-28: |
MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
Ottawa, Canada and Fleurus, Belgium ( PRN/ots ) - - Site to Provide Fluorodeoxyglucose ( F - 18 FDG ) for use in Earlier Detection of Disease and Therapy Management MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced (...) |
| 2008-09-01: |
SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI
Washington ( PRN/ots ) - - At One Year, Angioplasty and Stenting Matches Bypass Surgery for Safety and Effectiveness in Patients with Complex Medical Condition Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings (...) |
| 2008-01-28: |
Abbott's Kaletra( R ) and Aluvia( R ) ( lopinavir/ritonavir ) New Lower - Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Abbott Park, Illinois ( PRN/ots ) - - Lopinavir/ritonavir tablet is the first and only co - formulated protease inhibitor tablet approved for use in children with HIV Abbott ( NYSE: ABT ) announced today that the European Committee for Medicinal Products for Human Use ( CHMP ), (...) |
| 2010-02-22: |
Retacrit( TM ) to be the 1st Biosimilar Epoetin to Achieve Subcutaneous Licence in Renal Patients
London, February 22, 2010 ( PRN/ots ) - Hospira announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has recommended for approval the administration of Retacrit ( epoetin zeta ) subcutaneously in the nephrology setting. This provides an alternative option to intravenous ( IV ) delivery (...) |
| 2010-11-24: |
HOYA Faculty Education & Experience Centre Officially Opens its Doors
Budapest, Hungary, November 24 ( PRN/ots ) - On Tuesday evening November 9th around 110 invitees witnessed the opening ceremony of HOYA's new Faculty Education and Experience Centre in the heart of Budapest. Amongst the guests were Japanese Ambassador to Hungary Mr. Tecuo Ito and deputy (...) |
| 2005-04-22: |
Johnson & Johnson Proposed Acquisition of Guidant Corporation Enters Second Phase Review by European Commission
New Brunswick, New Jersey and Indianapolis ( PRN/ots ) - Johnson & Johnson and Guidant Corporation today announced that they have been notified, as anticipated, that the European Commission has decided to open a second phase review into the proposed acquisition of Guidant by Johnson (...) |
| 2008-02-22: |
Astellas Receives Positive Opinion From CHMP for Mycamine( R ) for the Treatment of Serious Fungal Infections
Staines, England ( PRN/ots ) - - New Treatment Option Contributes to Fight Against Healthcare Associated Infections Astellas Pharma Europe Ltd( i ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) issued a positive opinion by consensus, (...) |
| 2007-10-23: |
Two New Studies Provide Real World Data on Cardiovascular Events in CRESTOR Users
London ( PRN/ots ) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR( TM ) ( rosuvastatin ) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research ( ISPOR ) (...) |
| 2007-11-08: |
Study Finds New Version of QIAGEN's HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
Beijing, November 8 ( PRN/ots ) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH - - a non - profit global health (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
